Heres our full answer
Of specific concern would be factors that obscure a true increased risk of thyroid cancer with GLP1 receptor agonists, thereby influencing the interpretation of the study
Stomach pain : Approximately 20% of users experience abdominal pain or discomfort
Weight Loss and Dosage Needs Thyroid medication dosing is often related to body weight
This distinction matters not because B12 injections are inherently dangerous, but because the systems surrounding the injection determine how quickly and effectively a provider can respond if something unexpected occurs
These medicines include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist